CSE AIML | OTCQB AIMLF | FWB 42FB
PRESS RELEASE

AIML Subsidiary NeuralCloud Appoints Cardiac Monitoring Veterans Dale and Nicholas DuBois to Lead Clinical and Overread Operations

June 2, 2026
  • Appointments bring more than 50 combined years of cardiac monitoring, ECG overread (the expert clinical review of ECG recordings by trained technicians and cardiologists), and regulatory validation experience to NeuralCloud’s clinical and operational leadership team.
  • Leadership additions strengthen AIML’s clinical-governance and operational readiness as it advances its neural-network ECG signal-processing technology through regulatory review toward future commercialization.

Toronto, Canada, June 1, 2026. AI/ML Innovations Inc. (“AIML” or the “Company”), (CSE: AIML; OTCQB: AIMLF; FWB: 42FB), is pleased to announce that its wholly-owned subsidiary, NeuralCloud Solutions Inc. (“NeuralCloud”), has appointed Dale DuBois, ASN, as Clinical Operations Lead, and Nicholas DuBois, BS, CCT, as Vice President of Overread Operations. The appointments bring deep, hands-on cardiac monitoring leadership to NeuralCloud as the Company builds the clinical-governance and operational foundation to support its neural-network ECG signal-processing technology as it advances through the regulatory pathway.

Purpose-Built Operating Leadership for NeuralCloud’s Next Phase

NeuralCloud has reached an important stage in its evolution, advancing its neural-network ECG signal-processing technology through development, validation, and regulatory review. Dale and Nicholas DuBois join at exactly this inflection point, bringing the clinical-governance and operating expertise needed to build the standards, workflows, and team that will support the technology as it moves toward future commercialization.

Together, Dale and Nick bring more than 50 years of combined experience inside the cardiac monitoring industry. As co-founders of Global TeleMonitoring, LLC, they built, trained, and led the kind of clinical-governance and overread operation that NeuralCloud’s technology is being developed to support, giving them a rare operator’s perspective on the workflows the Company is building for.

Dale DuBois, Clinical Operations Lead

Dale DuBois brings more than 30 years of experience in cardiac monitoring operations, medical-device clinical leadership, and regulatory-facing validation, following a decade in bedside critical-care nursing earlier in her career. Most recently in executive leadership at Peerbridge Health, she established enterprise clinical governance, quality standards, and regulatory-aligned workflows supporting the delivery of more than 10,000 cardiac monitoring reports. She has led clinical-validation activities across ten clinical sites for FDA clearance, including Mount Sinai (New York), Northwell Health, Henry Ford Hospital, Hackensack Meridian Health, and Cone Memorial Hospital, and built and trained an overread team of more than 30 cardiac technicians. Beginning her career as a registered nurse in coronary and intensive care, Dale carries a patient-first clinical instinct into every governance decision. She is GCP-certified, was a CCRN-certified registered nurse, and is the founder of the Space Coast Chapter of the American Association of Critical-Care Nurses.

As Clinical Operations Lead, Dale will oversee NeuralCloud’s clinical governance, quality standards, and regulatory-aligned workflows, and serve as a senior clinical advisor as the Company prepares its technology for future commercialization.

Nicholas DuBois, Vice President of Overread Operations

Nicholas DuBois brings more than 20 years of experience leading ECG overread services, algorithm validation, and scalable ECG analysis and interpretation workflows. As co-founder of Global TeleMonitoring and, most recently, Director of Overread Services at Peerbridge Health, he built, trained, and managed overread teams of more than 25 cardiac technicians and designed workflows optimized for throughput, cost-efficiency, and quality control. He has led the validation and integration of multiple third-party ECG algorithms and workstations and partnered with research and product teams to refine algorithm performance and usability. He holds a Bachelor of Science from the University of North Florida and is a Certified Cardiac Technician (CCT) and GCP-certified.

As Vice President of Overread Operations, Nick will lead the design of NeuralCloud’s overread workflows, quality-control processes, and pilot and validation programs, building the operational capability the Company will rely on as its technology advances toward commercialization.

Leadership Commentary

“Dale and Nick are exactly the voices this market trusts,” said Paul Duffy, Executive Chairman and CEO of AIML. “Cardiac monitoring is a small, trust-based profession, and credibility comes from people who have run the floor themselves. Between them, Dale and Nick have built and led the kind of clinical operation our technology is being designed to support. Bringing that lived experience inside NeuralCloud strengthens our clinical and operational foundation as we advance through regulatory review.”

“I have spent my career building overread operations where quality and efficiency have to coexist,” said Nicholas DuBois, Vice President of Overread Operations of NeuralCloud. “What drew me to NeuralCloud is the chance to build that operational discipline from the ground up, with the rigor this field demands, as the Company advances its technology through development and regulatory review.”

“In more than three decades inside cardiac monitoring, I have learned that throughput means nothing without clinical governance and patient safety underneath it,” said Dale DuBois, Clinical Operations Lead of NeuralCloud. “What drew me to NeuralCloud is a team that puts that discipline first. I look forward to establishing the clinical standards and regulatory-aligned workflows that this work demands.”

Strengthening NeuralCloud’s Operating Platform

The appointments reflect NeuralCloud’s strategy of pairing AI innovation with deep operational expertise. Dale and Nick will work in close coordination with Erik Suokas, Chief Operating Officer, and alongside the Company’s Medical Advisory Board, with Dale and Nick leading the clinical-governance and operational standards that will underpin the Company’s technology and validation programs. Their addition strengthens NeuralCloud’s clinical and operational readiness while maintaining the regulatory discipline this field requires.

About AI/ML Innovations Inc.

AIML Innovations Inc. is a technology company developing artificial intelligence and neural-network solutions for digital health. Its proprietary technology applies advanced signal processing and deep learning to enhance the quality of complex biometric and cardiac signal data.

AIML’s shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

For detailed information please see AIML’s website or the Company’s filed documents at www.sedarplus.ca.

AIML Contact:

Paul Duffy, Executive Chairman and CEO

416-941-8900

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company’s products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Nothing in this news release should be construed as an offer to sell, or a representation regarding the regulatory status or commercial availability of, any product in any jurisdiction where it has not received the required regulatory authorization.

Read More

June 2, 2026
AIML Subsidiary NeuralCloud Appoints Cardiac Monitoring Veterans Dale and Nicholas DuBois to Lead Clinical and Overread Operations
Read More
May 11, 2026
AIML Appoints Dr. Martin Green to Medical Advisory Board and Issue Options
Read More
March 31, 2026
Neural Cloud Signs Reseller Agreement with European Digital Cardiac Monitoring Platform
Read More
March 27, 2026
AI/ML Innovations Inc. Announces Closing of First Tranche of Private Placement to Raise $950,000
Read More
March 25, 2026
AIML Subsidiary NeuralCloud Enters Research Services Agreement with Baker Heart and Diabetes Institute to Support AI-Driven ECG Analysis
Read More
March 12, 2026
AI/ML Innovations Inc. Announces Proposed Private Placement of Convertible Debentures
Read More
February 24, 2026
Neural Cloud Enters Distribution Agreement with Intelimed to Expand into Latin America
Read More
February 12, 2026
AIML Subsidiary NeuralCloud Signs Non-Binding Agreement with Movesense to Pilot AI-Powered ECG and Holter Reporting
Read More
February 10, 2026
Neural Cloud Retains Commission Wolf to Accelerate U.S. Commercial Expansion
Read More
January 28, 2026
AIML Appoints Dr. Paul Dorian as Medical Innovation Architect and Head of the Medical Advisory Board
Read More
January 20, 2026
AIML subsidiary NeuralCloud Collaborates with Movesense to Expand Bundled ECG Solutions for Clinical and Wellness Markets
Read More
January 8, 2026
AIML subsidiary NeuralCloud Solutions Inc., Signs Non-Binding Commercial Term Sheet with Lakeshore Cardiology to Deploy CardioYield™ for AI-Powered Holter Analysis
Read More
January 7, 2026
AIML Appoints Erik Suokas as Chief Operating Officer to Accelerate Commercial Execution and Operational Scale
Read More
December 30, 2025
AIML Announces the Conclusion of Consulting Agreement and Leadership Transition for President & Chief Commercial Officer
Read More
December 16, 2025
Join AIML’s Live Shareholder Update with Chairman & CEO Paul Duffy
Read More
December 9, 2025
AIML subsidiary NeuralCloud Solutions Signs Commercial Term Sheet with Culminate H Labs to Deploy MaxYield™ and Insight360™ into INTRINSICA's DNA-Guided Biofeedback Wellness Ecosystem
Read More
December 2, 2025
AIML subsidiary NeuralCloud Enters Pilot with Cornerstone Physiotherapy to Deploy MaxYield™ and Insight360™ for Elite Athlete Cardiac Performance Testing
Read More
November 26, 2025
AIML subsidiary NeuralCloud Signs Commercial Term Sheet with Equimetrics to Deploy MaxYield™ and CardioYield™ across Equine Cardiac Monitoring Platforms
Read More
November 24, 2025
AIML subsidiary Neural Cloud begins pilot at SickKids to Advance AI-Enabled Pediatric Cardiac Care
Read More
November 11, 2025
AI/ML Innovations Inc. Announces Grant of U.S. Patent Protecting Core ECG Signal-Processing Architecture
Read More
November 4, 2025
AIML Subsidiary NeuralCloud Solutions Engages Lonacas Consultants to Lead Regulatory Submission for CardioYield™ in Jamaica
Read More
October 21, 2025
AIML Subsidiary NeuralCloud Solutions Commencing Pilot with Canadian Cardiology Clinic to Advance AI-Powered ECG Reporting
Read More
October 15, 2025
AIML Subsidiary NeuralCloud Solutions and Heartdent Center Ltd. Launch Pilot Project to Advance Cardiac Care in Jamaica
Read More
October 7, 2025
AIML Subsidiary NeuralCloud Solutions and Toronto Heart Centre Launch a Pilot Program to Test AI-Powered Holter ECG Reporting
Read More
September 30, 2025
AIML and BC Brain Wellness Program Launch Pilot to Explore the Heart–Brain Connection
Read More
September 23, 2025
AIML Announces Closing of Oversubscribed Private Placement
Read More
September 4, 2025
AIML Announces Proposed Private Placement
Read More
August 21, 2025
AIML Announces SEDAR Filing
Read More
August 8, 2025
AIML Innovations Closes Quantum Sciences Ltd. Restructuring
Read More
June 10, 2025
AIML Strengthens IP Portfolio with Provisional Patents for AI Driven ECG Signal Processing
Read More
June 3, 2025
AIML Subsidiary Neural Cloud Signs LOI with Circular Health to License MaxYield™ ECG Signal-Processing
Read More
May 22, 2025
AIML Establishes Innovation Committee, Appoints Dr. Drew Dundas as Chair
Read More
May 20, 2025
AIML Establishes Medical Advisory Board to Drive AI Powered ECG Signal Processing Innovation
Read More
May 15, 2025
AIML Hits Key Regulatory Benchmark with 510(k) Filing for MaxYield™ Signal Enhancement Platform
Read More
May 5, 2025
AIML Innovations Appoints Political Strategist and Public Affairs Leader, Michael Diamond, to Board of Directors
Read More
April 25, 2025
AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Read More
April 25, 2025
AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Read More
April 22, 2025
AIML Innovations Appoints Jared Adelstein to Board of Directors
Read More
April 15, 2025
AIML Announces Closing of Oversubscribed Private Placement
Read More
April 7, 2025
AIML Updates Terms of Proposed Private Placement Announced
Read More
April 4, 2025
AIML Announces Proposed Private Placement
Read More
January 9, 2025
AI/ML Innovations Inc. Welcomes Industry Trailblazers to Board of Directors
Read More
January 23, 2025
AI/ML Innovations Inc. Appoints Dr. Alan Rabinowitz as Chief Medical Officer and Director of Medical Partnerships
Read More
January 28, 2025
Andrea Ruth Joins AI/ML Innovations as Head of Quality, Clinical, and Regulatory Affairs
Read More
February 20, 2025
Key Updates to Upcoming Annual and Special Meeting
Read More
March 14, 2025
AIML Aligns Leadership for Growth and Shareholder Value Creation
Read More
March 21, 2025
AIML Continues to Streamline for the Future and Moves Beyond Tech2Heal
Read More